MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.0009
NaN%
Closed 09:30 05/22 EDT
OPEN
--
PREV CLOSE
0.0009
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.014
52 WEEK LOW
0.0009
MARKET CAP
9.79M
P/E (TTM)
-0.9000
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Barchart · 3d ago
Alterity Therapeutics publishes quantitative susceptibility mapping MRI data
TipRanks · 05/11 12:01
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Barchart · 05/07 06:25
Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push
TipRanks · 05/07 01:42
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 04/30 06:25
Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing
TipRanks · 04/30 01:43
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Alterity Therapeutics (OtherPRNAF)
TipRanks · 04/30 00:00
Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026
TipRanks · 04/29 03:07
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.